Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.47 |
| ▸ | AHR | P35869 | 2/20 | 0.47 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.47 |
| ▸ | VDR | P11473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.46 |
| ▸ | RELA | Q04206 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24217120 | 0.83 | CYP19A1 (0.57) | CYP19A1CLK4DYRK1ANR1H2NR1H3 | |
| SCHEMBL20320401 | 0.83 | DYRK1A (0.60) | CYP19A1CLK4DYRK1ANR1H2NR1H3 | |
| SCHEMBL30423929 | 0.83 | CYP19A1 (0.57) | CYP19A1CLK4DYRK1ANR1H2NR1H3 | |
| SCHEMBL14488273 | 0.81 | CYP19A1 (0.56) | CYP19A1CLK4DYRK1ANR1H2NR1H3 | |
| SCHEMBL9867568 | 0.80 | ADORA3 (0.54) | CLK4SMN1; SMN2RAB9ANPC1TP53 | |
| SCHEMBL23042515 | 0.79 | RAB9A (0.50) | CYP1A2CYP3A4CYP2C9NR1I3SMN1; SMN2 | |
| SCHEMBL9867758 | 0.78 | CYP19A1 (0.52) | CYP19A1CLK4DYRK1ANR1H2NR1H3 | |
| SCHEMBL30287350 | 0.77 | CYP19A1 (0.73) | CYP19A1CLK4DYRK1ANR1H2NR1H3 | |
| SCHEMBL28406603 | 0.77 | CYP19A1 (0.73) | CYP19A1CLK4DYRK1ANR1H2NR1H3 | |
| SCHEMBL9867042 | 0.77 | CYP19A1 (0.54) | CYP19A1CLK4DYRK1ANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472166-B2 | Inhibition of mycobacterial type VII secretion | STICHTING VUMC (NL) | 2025-11-18 | — | — | US | disclosed |
| EP-4021898-B1 | INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION | Stichting Amsterdam UMC (NL) | 2024-05-29 | — | — | EP | disclosed |
| US-20220280487-A1 | INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION | STICHTING VU (NL) | 2022-09-08 | — | — | US | disclosed |
| EP-4021898-A1 | INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION | Stichting VUmc (NL) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021040519-A1 | INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION | STICHTING VUMC (NL) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021040519-A1 | INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION | STICHTING VUMC (NL) | 2021-03-04 | — | — | WO | disclosed |
| US-4985450-A | TREATMENT OF GLAUCOMA | AVENTIS PHARMACEUTICALS INC. | 1991-01-15 | — | — | US | disclosed |
| US-4873239-A | GLAUCOMA TREATMENT | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-10-10 | — | — | US | disclosed |
| EP-0276822-A1 | Arylthiadiazolylsulfonamides and derivatives, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-08-03 | — | — | EP | disclosed |
| US-4758578-A | Arylthiadiazolylsulfonamides, pharmaceutical compositions and use | HOECHST ROUSSEL PHARMACEUTICALS, INC. (US) | 1988-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12472166-B2 | Inhibition of mycobacterial type VII secretion | CFTR, ABCB11, ABCC2 | CYP19A1 4478/4885CLK4 1482/4885DYRK1A 3710/4885 |
| US-20220280487-A1 | INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION | CFTR, ABCB11, ABCC2 | CYP19A1 4478/4885CLK4 1482/4885DYRK1A 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.